BEACHBODY CO INC/THE (BODI) Stock Fundamental Analysis
USA - NASDAQ:BODI - US0734633094 - Common Stock
4.77 USD
-0.08 (-1.65%)
BODI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 78 industry peers in the Diversified Consumer Services industry. BODI has a bad profitability rating. Also its financial health evaluation is rather negative. BODI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year BODI has reported negative net income.
BODI had a positive operating cash flow in the past year.
BODI had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BODI reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -39.90%, BODI is not doing good in the industry: 75.64% of the companies in the same industry are doing better.
BODI's Return On Equity of -288.76% is on the low side compared to the rest of the industry. BODI is outperformed by 78.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.9% | ||
| ROE | -288.76% | ||
| ROIC | N/A |
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BODI has a better Gross Margin (70.02%) than 83.33% of its industry peers.
In the last couple of years the Gross Margin of BODI has remained more or less at the same level.
BODI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
2. Health
2.1 Basic Checks
BODI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BODI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BODI has less shares outstanding
BODI has a worse debt/assets ratio than last year.
2.2 Solvency
BODI has an Altman-Z score of -4.78. This is a bad value and indicates that BODI is not financially healthy and even has some risk of bankruptcy.
BODI's Altman-Z score of -4.78 is on the low side compared to the rest of the industry. BODI is outperformed by 75.64% of its industry peers.
A Debt/Equity ratio of 1.16 is on the high side and indicates that BODI has dependencies on debt financing.
BODI has a Debt to Equity ratio of 1.16. This is in the lower half of the industry: BODI underperforms 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.78 |
ROIC/WACCN/A
WACC10.7%
2.3 Liquidity
BODI has a Current Ratio of 0.60. This is a bad value and indicates that BODI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.60, BODI is not doing good in the industry: 75.64% of the companies in the same industry are doing better.
A Quick Ratio of 0.48 indicates that BODI may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.48, BODI is doing worse than 79.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.48 |
3. Growth
3.1 Past
BODI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.99%, which is quite impressive.
The Revenue for BODI has decreased by -31.97% in the past year. This is quite bad
The Revenue for BODI have been decreasing by -11.14% on average. This is quite bad
EPS 1Y (TTM)42.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.7%
Revenue 1Y (TTM)-31.97%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-41.97%
3.2 Future
Based on estimates for the next years, BODI will show a very strong growth in Earnings Per Share. The EPS will grow by 32.75% on average per year.
Based on estimates for the next years, BODI will show a very negative growth in Revenue. The Revenue will decrease by -25.27% on average per year.
EPS Next Y72.98%
EPS Next 2Y32.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-40.64%
Revenue Next 2Y-25.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BODI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BODI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
BODI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BODI is cheaper than 97.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.51 |
4.3 Compensation for Growth
A more expensive valuation may be justified as BODI's earnings are expected to grow with 32.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
BODI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BODI (11/3/2025, 8:00:01 PM)
4.77
-0.08 (-1.65%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)
Earnings (Next)
Inst Owners40.03%
Inst Owner ChangeN/A
Ins Owners5.24%
Ins Owner Change-1.32%
Market Cap33.72M
Revenue(TTM)324.87M
Net Income(TTM)-58209000
Analysts80
Price Target8.67 (81.76%)
Short Float %5.19%
Short Ratio13.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.74%
Min EPS beat(2)14.53%
Max EPS beat(2)42.94%
EPS beat(4)3
Avg EPS beat(4)7.78%
Min EPS beat(4)-77.42%
Max EPS beat(4)51.05%
EPS beat(8)4
Avg EPS beat(8)-3.9%
EPS beat(12)6
Avg EPS beat(12)-5.4%
EPS beat(16)8
Avg EPS beat(16)-9.68%
Revenue beat(2)2
Avg Revenue beat(2)8.97%
Min Revenue beat(2)7.39%
Max Revenue beat(2)10.54%
Revenue beat(4)3
Avg Revenue beat(4)5.09%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)10.54%
Revenue beat(8)5
Avg Revenue beat(8)3.32%
Revenue beat(12)7
Avg Revenue beat(12)2.29%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)0%
PT rev (3m)-17.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)58.26%
EPS NY rev (1m)0%
EPS NY rev (3m)36.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.1 | ||
| P/FCF | N/A | ||
| P/OCF | 36.15 | ||
| P/B | 1.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 2.51 |
EPS(TTM)-7.52
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)0.13
OCFY2.77%
SpS45.95
BVpS2.85
TBVpS-7.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.9% | ||
| ROE | -288.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% | ||
| FCFM | N/A |
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
F-Score5
Asset Turnover2.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.83 | ||
| Cap/Depr | 10.93% | ||
| Cap/Sales | 1.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 7.32% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.48 | ||
| Altman-Z | -4.78 |
F-Score5
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)15.58%
Cap/Depr(5y)44.94%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.7%
EPS Next Y72.98%
EPS Next 2Y32.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-31.97%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-41.97%
Revenue Next Year-40.64%
Revenue Next 2Y-25.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y61.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y92.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.3%
OCF growth 3YN/A
OCF growth 5Y-42.85%
BEACHBODY CO INC/THE / BODI FAQ
What is the ChartMill fundamental rating of BEACHBODY CO INC/THE (BODI) stock?
ChartMill assigns a fundamental rating of 1 / 10 to BODI.
What is the valuation status for BODI stock?
ChartMill assigns a valuation rating of 2 / 10 to BEACHBODY CO INC/THE (BODI). This can be considered as Overvalued.
How profitable is BEACHBODY CO INC/THE (BODI) stock?
BEACHBODY CO INC/THE (BODI) has a profitability rating of 2 / 10.
What is the financial health of BEACHBODY CO INC/THE (BODI) stock?
The financial health rating of BEACHBODY CO INC/THE (BODI) is 0 / 10.
Can you provide the expected EPS growth for BODI stock?
The Earnings per Share (EPS) of BEACHBODY CO INC/THE (BODI) is expected to grow by 72.98% in the next year.